Search Results

OBJECTIVE: To compare the efficacy and safety of different chemotherapy regimens in elderly multiple myeloma (MM) patients with different Frailty scores. METHODS: The clinical data of elderly patients with MM were retrospectively analyzed, including age, treatment regimen, efficacy, adverse reactions, and the Frailty score included in the activity of daily living score, the instrumental activity of daily living scale and the Charlson comorbidity index. The patients were divided into fit group, mediate fit group and frail group according to the scoring standard. The treatment efficiency and adverse reaction rates of elderly MM with different physical conditions treated by different chemotherapy regimens were analyzed. RESULTS: Among the 70 patients, the effective rates of the patients in fit group, the mediate fit group, and the frail group were 79.5%, 81%, and 40%, and the effective rates of the fit patients in double and triple groups were 54.5% and 89.3%, 70% and 90.9% for mediate fit patients, 42.9% and 33.3% for frail patients, the triple regimen in fit patients showed obvious advantages, and the difference showed statistically significant (P<0.05), while the efficacy for mediate patients and frail patients showed no significant difference. During the induction of bortezomib, the incidence of adverse reactions for the patients in the triple group (78.6%) was higher than 67.9% in the double group, and the difference showed no statistically significant (P>0.05).There was no significant difference in the 1-year overall survival rate of the patients and with molecular genetic abnormalities among each groups. CONCLUSION The therapeutic effect is related to the patient's physical condition. For patients with healthy physique, the triple regimen should be used first. For patients with weak physical constitution, the chemotherapy regimen with low drug toxicity should be selected for safety.
Aged ; Bortezomib ; Frailty ; Humans ; Multiple Myeloma/drug therapy* ; Retrospective Studies

1.Combination chemotherapy for the treatment of multiple myeloma.

2.Clinical benefit and regimen selection for patients with newly-diagnosed multiple myeloma in the era of novel agents.

3.Biology study and novel drugs for targeting therapy of multiple myeloma.

4.Bortezomib-based four-drug combination regimen improved the efficacy of multiple myeloma patients receiving previous doublet or triplet regimens containing Bortezomib.

5.Strategic consideration on treatment of multiple myeloma.

6.Combination chemotherapy with vincristine, melphalan and prednisone for multiple myeloma.

7.A Case of Phagocytic Myeloma after Chemotherapy.

8.Nonsecretory Multiple Myeloma associated with Immune Thrombocytopenia and Complicated by Malignant Ascites.

9.High Dose Chemotherapy with Autologous Stem Cell Transplantation on Multiple Myeloma.

10.Evaluation of the Efficacy and Safety of Chemotherapy in Elderly Patients with Multiple Myeloma under Different Frailty Scores.

Display Mode

Output Records

File Type